Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing

Cancer Cytopathology

Volumn 122, Issue 11, 2014, Pages 822-832

  Gleeson, Ferga C ^a   Kipp, Benjamin R ^a   Levy, Michael J ^a   Voss, Jesse S ^a   Campion, Michael B ^a   Minot, Douglas M ^a   Tu, Zheng J ^a   Klee, Eric W ^a   Lazaridis, Konstantinos N ^a   Kerr, Sarah E ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

cytopathology; fine needle aspiration; lung cancer adrenal metastasis; next generation sequencing; personalized medicine; targeted therapy; variant interpretation

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN RET;

ADRENAL GLAND; ADRENAL METASTASIS; AGED; ARTICLE; BRAF GENE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CYTOLOGY; DNA EXTRACTION; EGFR GENE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE; GENOTYPE; GNAS GENE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; ONCOGENE RET; PIK3CA GENE; PREVALENCE; PRIORITY JOURNAL; PTEN GENE; RB1 GENE; SMALL CELL LUNG CANCER; SMEAR; SMOKING; STK11 GENE; TOUCH PREPARATION SMEAR; TP53 GENE; ADRENAL GLAND NEOPLASMS; CYTODIAGNOSIS; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PAPANICOLAOU TEST; PATHOLOGY; PROCEDURES; SECONDARY; VERY ELDERLY;

ADRENAL GLAND NEOPLASMS; AGED; AGED, 80 AND OVER; CYTODIAGNOSIS; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PAPANICOLAOU TEST;

EID: 84908411956     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21464     Document Type: Article

References (31)

1. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (suppl 5): e341S-e368S.
2. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013; 8: 823-859.
3. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008; 99: 923-929.
4. Han HS, Eom DW, Kim JH, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer. 2011; 12: 380-386.
5. Gow CH, Chang YL, Hsu YC, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2009; 20: 696-702.
6. Park S, Holmes-Tisch AJ, Cho EY, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol. 2009; 4: 809-815.
7. Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S,. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol. 2010; 41: 94-102.
8. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M,. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009; 15: 4554-4560.
9. Bozzetti C, Tiseo M, Lagrasta C, et al. Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites. J Thorac Oncol. 2008; 3: 18-22.
10. Daniele L, Cassoni P, Bacillo E, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol. 2009; 4: 684-688.
11. Khode R, Larsen DA, Culbreath BC, et al. Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer (Cancer Cytopathol). 2013; 121: 361-369.
12. Bellevicine C, Malapelle U, de Luca C, Iaccarino A, Troncone G,. EGFR analysis: current evidence and future directions [published online ahead of print March 12, 2014]. Diagn Cytopathol. doi: 10.1002/dc.23142.
13. Wood SL, Pernemalm M, Crosbie PA, Whetton AD,. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014; 40: 558-566.
14. Scarpa A, Sikora K, Fassan M, et al. Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One. 2013; 8: e80478.
15. Buttitta F, Felicioni L, Del Grammastro M, et al. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res. 2013; 19: 691-698.
16. Young G, Wang K, He J, et al. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer (Cancer Cytopathol). 2013; 121: 688-694.
17. Billah S, Stewart J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer (Cancer Cytopathol). 2011; 119: 111-117.
18. Karnes HE, Duncavage EJ, Bernadt CT,. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung. Cancer (Cancer Cytopathol). 2014; 122: 104-113.
19. Bellevicine C, Vita GD, Malapelle U, Troncone G,. Applications and limitations of oncogene mutation testing in clinical cytopathology. Semin Diagn Pathol. 2013; 30: 284-297.
20. Bediaga NG, Davies MP, Acha-Sagredo A, et al. A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material. Br J Cancer. 2013; 109: 2404-2411.
21. Fischer AH, Cibas ES, Howell LP, et al. Role of cytology in the management of non-small-cell lung cancer. J Clin Oncol. 2011; 29: 3331-3332; author reply 3332-3333.
22. An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One. 2012; 7: e40109.
23. Liu Y, Marks K, Cowley GS, et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 2013; 3: 870-879.
24. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18: 378-381.
25. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012; 18: 375-377.
26. Liu P, Morrison C, Wang L, et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis. 2012; 33: 1270-1276.
27. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489: 519-525.
28. Rosell R, Carcereny E, Gervais R, et al. Spanish Lung Cancer Group in collaboration with Groupe Francais de Pneumo-Cancerologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246.
29. de Biase D, Visani M, Malapelle U, et al. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy). PLoS One. 2013; 8: e83607.
30. Kim HR, Cho BC, Shim HS, et al. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Lung Cancer. 2014; 83: 374-382.
31. Davare MA, Saborowski A, Eide CA, et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci U S A. 2013; 110: 19519-19524.